Login / Signup

Imiquimod-enhanced immunotherapy with diphencyprone for patients with alopecia areata.

Borja Diaz-GuimaraensDavid Saceda-CorraloÁngela Hermosa-GelbardOscar M Moreno-ArronesMiguel Dominguez-SantasAna Suarez-ValleSergio Vañó-Galván
Published in: Dermatologic therapy (2022)
Topical immunotherapy with dyphencyprone (DPCP) is widely used in patients with alopecia areata (AA). It can produce a contact dermatitis that is believed to decrease Th1 response, predominant in AA. It has been shown that imiquimod (IMQ), a topical immunomodulator drug, can produce sensitization to DPCP in patients that do not show signs of contact dermatitis when exposed to DPCP. Nevertheless, there is no evidence as to whether it can improve DPCP efficacy in already sensitized patients. We present a series of 9 patients, (7 females [77%] and 2 males [22%]) with a mean age of 38.4 years (range, 19-60 years), successfully sensitized to DPCP, that were treated with a combination of DPCP and IMQ. The mean SALT (Severity of Alopecia Tool) score before adding IMQ was 43.3 (range, 10-60), and the mean number of months of DPCP use prior to the addition of IMQ was 6.8 (range 0-10). After adding IMQ to their DPCP treatment, 77% of the patients had further improvement, with a mean SALT reduction of 13.3 (range, [-50] - 40), and a mean duration of response of 5.2 months. No adverse effects were reported. According to this data, we believe that the combination of DPCP and IMQ can be a promising way of improving the efficacy of contact immunotherapy in AA, and requires further study.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • emergency department
  • machine learning
  • deep learning
  • patient reported
  • replacement therapy
  • drug induced